Hapten-modified autologous tumor-associated antigens

Hapten-modified autologous tumor-associated antigens are a personalized immunotherapy component used to stimulate a patient's immune system against cancer cells. This approach involves harvesting tumor cells from a patient, isolating the tumor-associated antigens, and chemically conjugating them with a small molecule called a hapten, such as dinitrophenyl (DNP) [1]. The addition of the hapten makes the tumor antigens appear foreign to the immune system, thereby overcoming the natural immune tolerance that tumors often exploit to survive [2]. Once administered back into the patient, these modified antigens are processed by antigen-presenting cells and presented to T-cells, triggering a systemic immune response [3]. This response includes the activation of cytotoxic T-lymphocytes that can specifically target and destroy unmodified tumor cells throughout the body [1]. This strategy has been primarily explored in the treatment of melanoma and ovarian cancer to prevent recurrence and treat metastatic disease [2, 3].

Other names

DNP-modified autologous tumor cellsDinitrophenyl-conjugated tumor antigensHapten-conjugated autologous tumor antigensDNP-Vax

The mechanism involves the chemical conjugation of a hapten (e.g., dinitrophenyl) to autologous tumor antigens, which increases their immunogenicity by creating a foreign epitope on self-antigens [1]. This modification facilitates the uptake and processing by professional antigen-presenting cells (APCs), which then present both the hapten and the tumor-associated antigens (TAAs) to T-cells via MHC molecules [2]. This process breaks immunological tolerance, leading to the activation of CD4+ helper and CD8+ cytotoxic T-lymphocytes that can recognize and eliminate unmodified tumor cells expressing the same TAAs [3].